Clinically-oriented therapies in sepsis: A review

Journal of Endotoxin Research

Volumn 6, Issue 6, 2000, Pages 463-469

  Dubois, M J ^a   Vincent, J L ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; ARACHIDONIC ACID; COMPLEMENT INHIBITOR; CORTICOSTEROID; DELTIBANT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTOXIN; GINKGOLIDE B; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; KALLIKREIN; KININ; LEXIPAFANT; MAK 195 F; MONOCLONAL ANTIBODY; POLYMYXIN B; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P55; PROTEIN P75; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HEMOFILTRATION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; KALLIKREIN KININ SYSTEM; MACROPHAGE; NEUTROPHIL; REVIEW; SEPSIS; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; ENDOTOXINS; HEMOFILTRATION; HUMANS; INTERLEUKIN-1; PLATELET ACTIVATING FACTOR; SEPSIS; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS);

EID: 0034448258     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805100101532432     Document Type: Article

References (60)

1. The cardiovascular response of normal humans to the administration of endotoxin
2. Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial
3. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
4. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial
5. E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis. A randomized controlled trial
6. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin
7. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind placebo-controlled trial
8. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock
9. The French national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients
10. Role of the bactericidal/permeability-increasing protein in host defence
11. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
12. Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from Gram-positive infection
13. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men
14. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock
15. Effect of high-dose glucocorticosteroid therapy on mortality in patients with clinical signs of systemic sepsis
16. Steroid controversy in sepsis and septic shock: A meta-analysis
17. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature
18. Reversal of late septic shock with supraphysiologic doses of hydrocortisone
19. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
20. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
21. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis
22. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock
23. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
24. Plasma cytokines and endotoxin levels correlate with survival in patients with sepsis syndrome
25. Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The RAMSES study
26. Proinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock
27. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
28. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock
29. Interleukin-1 receptor antagonist: Role in biology
30. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome
31. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double blind, placebo-controlled, multicenter trial
32. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127)
33. Coagulation inhibitor substitution during sepsis
34. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled, double-blind, randomized, multicenter study
35. The role of the endothelium in modulating vascular control in sepsis and related conditions
36. Administration of an antibody to E-selectin in patients with septic shock
37. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
38. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
39. Phase II multicenter clinical study of the platelet activating factor BB-882 in the treatment of sepsis
40. Lipid mediators in the pathophysiology of critical care illness
41. A multicenter, double blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome
42. The effects of ibuprofen on physiology and survival of patients with sepsis
43. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. A randomized controlled trial
44. Redox imbalance in the critically ill
45. Does N-acetyl-L-cysteine influence cytokine response during early septic shock?
46. Administration of albumin to patients with sepsis syndrome: A possible role in plasma thiol repletion
47. Nitric oxide in the pathogenesis of sepsis
48. Multicenter, randomized, placebo-controlled, double blind study of nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
49. Hemofiltration in sepsis and septic shock
50. Endotoxin filtration and immune stimulation improve survival from Gram-negative sepsis
51. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial
52. Interferon-γ in the prevention of severe burn-related infections: A European phase III multicenter trial
53. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
54. Prophylactic granulocyte colony-stimulating factor in critically ill patients: Not time yet
55. Apoptosis in sepsis
56. Why sepsis trials fail
57. Search for effective immunomodulating strategies against sepsis
58. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
59. Should morbidity replace mortality as en endpoint for clinical trials in intensive care?
60. Use of the SOFA score to assess the incidence of organ dysfunction score/failure in intensive care units: Results of a multicenter, prospective study